Re NHS Review

Deltex Medical Group PLC
14 July 2004

14 July 2004


            Deltex Medical Group plc ('Deltex Medical' / 'Company')

NHS HOSPITAL REVIEW DEMONSTRATES USE OF DELTEX MEDICAL'S CARDIOQ REDUCES LENGTH
                          OF HOSPITAL STAY BY TWO DAYS


Deltex Medical, the AIM listed haemodynamic monitoring company, today announces
the results of a formal post-procurement review by Medway NHS Trust (the '
Trust') on the impact of the wide scale use of Deltex Medical's CardioQ system.
This review was undertaken subsequent to the Trust's decision to adopt the
Company's technology announced to shareholders on 14 April 2004.

The findings of the independent review demonstrate that the use of the CardioQ
leads to an average reduction in the length of hospital stay of approximately
two days per patient and have led the Trust to confirm its initial minimum order
for ten CardioQs and 570 disposable probes.  The total sale is valued at £83,000
and represents the largest single order funded out of mainstream NHS operational
funds in the Company's history.

The objectives of the Trust's review were firstly to ensure that it could
implement the technology successfully and deliver the expected benefits in
length of stay reductions and, secondly, to determine the extent to which the
Trust would be prepared to fund ongoing routine use of the CardioQ system.

The Trust's conclusion was that the average reductions in length of hospital
stay of approximately two days per patient across a wide range of surgical
procedures could be attributed directly to the use of the CardioQ.  As a result,
the Trust has stated that its managers, anaesthetists and surgeons will now work
together to ensure that the use of the CardioQ is established as a standard of
care on as many as possible of the 7,500 moderate and major risk surgical
patients treated by the Trust each year.

The Company will be using the Medway NHS Trust results to demonstrate to
decision makers throughout the NHS that they will quickly improve clinical
outcomes whilst benefiting from significantly better economic performance if
they use the CardioQ system.

Deltex Medical's Chief Executive, Andy Hill, commented:

'The highly controlled environment of clinical trials has shown repeatedly that
use of Deltex Medical's CardioQ technology helps patients get better, quicker.
The result of the Trust's review demonstrates exactly the same positive impact
in the real-world setting of a typical NHS district general hospital.  The value
of the benefit achieved by the Trust is several times the cost of using the
Company's products.  The reduction in stay achieved by the Trust is consistent
with the results emerging from similar reviews being undertaken at other NHS
Trusts.

'The findings of this review are a transformational step forward in the way in
which Deltex Medical will unequivocally be able to demonstrate to decision
makers throughout the NHS that they can quickly improve clinical outcomes whilst
benefiting from significantly better economic performance if they use the
CardioQ system.'


For further information, please contact:-

Deltex Medical Group plc
Nigel Keen, Chairman
[e-mail]
01243 774 837

Andy Hill, Chief Executive
[e-mail]
01243 774 837

Ewan Phillips, Finance Director
[e-mail]
01243 774 837

Financial Dynamics
Stephanie Highett
[e-mail]
020 7831 3113


Notes to Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange